Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy
- 1 July 2017
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 98 (4) , 858-867
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and ConfoundersCancer Prevention Research, 2014
- Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma – A systematic reviewRadiotherapy and Oncology, 2014
- Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous CarcinomaJournal of Clinical Oncology, 2009
- Head and neck cancer in the elderly: An overview on the treatment modalitiesCancer Treatment Reviews, 2009
- Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck CancersJNCI: Journal of the National Cancer Institute, 2008
- Polypharmacy in elderly patientsThe American Journal of Geriatric Pharmacotherapy, 2007
- Comorbidity Is a Prognostic Factor in Elderly Patients with Head and Neck CancerAnnals of Surgical Oncology, 2007
- Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survivalCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2005
- Comorbidity and survival of elderly head and neck carcinoma patientsCancer, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987